IP Library › Granted Patent US 9,988,420

Granted Patent B2

US 9,988,420 · App. 15/104,727 · Granted Jun 5, 2018

Cytotoxic peptides and conjugates thereof

Inventors: Bernhard Hubert Geierstanger (Solana Beach, CA); Jan Grunewald (San Diego, CA); Weijia Ou (San Diego, CA); Tetsuo Uno (San Diego, CA); Yongqin Wan (Irvine, CA); Xing Wang (San Diego, CA); Yunho Jin (San Diego, CA)

Assignee: Novartis AG

C07K5/0205 A61K47/6817 A61K47/6851 C07K7/02 C07K16/32

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 9,988,420
App. No.: 15/104,727
Granted: Jun 5, 2018
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.

Claims (315)

1. A compound or stereoisomer thereof having the structure of Formula (I)

wherein:

R 1 is a C-linked 6 membered heterocycloalkyl containing 1-2 N heteroatoms and a C 1 -C 2 alkylene bridge or R 1 is a C-linked 5-8 membered fused bicyclic heterocycloalkyl containing 1-2 N heteroatoms, wherein each is unsubstituted, or each is substituted with an R 7 and 0 to 3 substituents independently selected from R 5 and R 6 , or each is substituted with 1 to 3 substituents independently selected from R 5 and R 6 ;

R 2 is —C 1 -C 6 alkyl;

R 3 is

R 4 is —OH, C 1 -C 6 alkoxy, —N(R 14 ) 2 , —R 16 , —NR 12 (CH 2 ) m N(R 14 ) 2 , —NR 12 (CH 2 ) m R 16 , -LR 9 , —NHS(O) 2 R 11 , —NHS(O) 2 (CH 2 ) m N 3 , —NHS(═O) 2 LR 9 ,

R 5 is C 1 -C 6 alkyl, —C(═O)R 11 , —(CH 2 ) m OH, —C(═O)(CH 2 ) m OH, —C(═O)((CH 2 ) m O) n R 12 , —((CH 2 ) m O) n R 12 , or C 1 -C 6 alkyl which is optionally substituted with —CN, —C(═O)NH 2 or 1 to 5 hydroxyl;

R 6 is halo, oxo, OH, C 1 -C 6 alkyl, —N(R 14 ) 2 , —R 16 and —NR 12 C(═O)R 11 ;

R 7 is LR 9 ;

R 8 is H or LR 9 ;

each L is independently selected from -L 1 L 2 L 3 L 4 L 5 L 6 - , -L 6 L 5 L 4 L 3 L 2 L 1 -, -L 1 L 2 L 3 L 4 L 5 -, -L 5 L 4 L 3 L 2 L 1 -, -L 1 L 2 L 3 L 4 -, -L 4 L 3 L 2 L 1 -, -L 1 L 2 L 3 -, -L 3 L 2 L 1 -, -L 1 L 2 -, -L 2 L 1 - and -L 1 ,

wherein

L 1 is selected from:

—(CH 2 ) m —, —C(═O)(CH 2 ) m —, —C(═O)X 1 X 2 C(═O)(CH 2 ) m —, —C(═O)X 1 X 2 C(═O)(CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —C(═O)X 1 X 2 C(═O)(CH 2 ) m X 3 (CH 2 ) m —, —C(═O)X 1 X 2 C(═O)((CH 2 ) m O) n (CH 2 ) m —, —C(═O)X 1 X 2 C(═O)((CH 2 ) m O) n (CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —C(═O)X 1 X 2 C(═O)((CH 2 ) m O) n (CH 2 ) m NR 12 C(═O)(CH 2 ) m X 3 (CH 2 ) m —, —C(═O)X 1 X 2 C(═O)((CH 2 ) m O) n (CH 2 ) m X 3 (CH 2 ) m —, —C(═O)X 1 X 2 C(═O)(CH 2 ) m NR 12 C(═O)((CH 2 ) m O) n (CH 2 ) m —, —C(═O)X 1 X 2 C(═O)(CH 2 ) m NR 12 C(═O)((CH 2 ) m O) n (CH 2 ) m X 3 (CH 2 ) m —, —C(═O)X 1 X 2 (CH 2 ) m X 3 (CH 2 ) m —, —C(═O)X 1 X 2 ((CH 2 ) m O) n (CH 2 ) m —, —C(═O)X 1 X 2 ((CH 2 ) m O) n (CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —C(═O)X 1 X 2 ((CH 2 ) m O) n (CH 2 ) m NR 12 C(═O)(CH 2 ) m X 3 (CH 2 ) m —, —C(═O)X 1 X 2 ((CH 2 ) m O) n (CH 2 ) m X 3 (CH 2 ) m —, —C(═O)X 1 X 2 (CH 2 ) m NR 12 ((CH 2 ) m O) n (CH 2 ) m —, —C(═O)X 1 X 2 C(═O)(CH 2 ) m NR 12 ((CH 2 ) m O) n (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —C(═O)((CH 2 ) m O) n (CH 2 ) m —, —(CH 2 ) m S(═O) 2 ((CH 2 ) m O) n (CH 2 ) m —, —C(═O)(CH 2 ) m NR 12 (CH 2 ) m —, —C(═O)NR 12 (CH 2 ) m —, —C(═O)NR 12 (CH 2 ) m X 3 (CH 2 ) m —, —C(═O)NH(CH 2 ) m NR 12 C(═O)X 1 X 2 C(═O)(CH 2 ) m —, —C(═O)(CH 2 ) m X 3 ((CH 2 ) m O) n —, —C(═O)X 1 C(═O)NR 12 (CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —C(═O)X 1 C(═O)NR 12 (CH 2 ) m X 3 (CH 2 ) m —, —C(═O)NR 12 (CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —C(═O)NR 12 (CH 2 ) m NR 12 C(═O)(CH 2 ) m X 3 (CH 2 ) m —,

—(CH 2 ) m C(═O)NR 12 (CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —(CH 2 ) m C(═O)—, —(CH 2 ) m C(═O)X 2 X 1 C(═O)—, —(CH 2 ) m X 3 (CH 2 ) m C(═O)X 2 X 1 C(═O)—, —(CH 2 ) m C(═O)NR 12 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m C(═O)NR 12 (CH 2 ) m —, —(CH 2 ) m NR 12 C(═O)(CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m (O(CH 2 ) m ) n C(═O)—, —(CH 2 ) m (O(CH 2 ) m ) n S(═O) 2 (CH 2 ) m —, —(CH 2 ) m NR 12 (CH 2 ) m C(═O)—, —(CH 2 ) m NR 12 C(═O)—, —(CH 2 ) m C(═O)X 2 X 1 C(═O)NR 12 (CH 2 ) m NHC(═O)—, —(CH 2 ) m C(═O)NR 12 (CH 2 ) m NR 12 C(═O)X 1 —, —(CH 2 ) m C(═O)NR 12 (CH 2 ) m NR 12 C(═O)—,

—((CH 2 ) m O) n (CH 2 ) m —, —(CH 2 ) m (O(CH 2 ) m ) n —, —(CH 2 ) m (O(CH 2 ) m ) n X 3 (CH 2 ) m —, —(CH 2 ) m X 3 ((CH 2 ) m O) n (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m C(═O)—, —C(═O)(CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m (O(CH 2 ) m ) n C(═O)—, —C(═O)((CH 2 ) m O) n (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m C(═O)NR 12 (CH 2 ) m C(═O)—, —C(═O)(CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —C(═O)(CH 2 ) m NR 12 C(═O)O(CH 2 ) m —, —(CH 2 ) m OC(═O)NR 12 (CH 2 ) m C(═O)—, —S(═O) 2 (CH 2 ) m NR 12 C(═O)O(CH 2 ) m —, —(CH 2 ) m OC(═O)NR 12 (CH 2 ) m S(═O) 2 —, —(CH 2 ) m C(═O)NR 12 (CH 2 ) m (O(CH 2 ) m ) n C(═O)—, —C(═O)((CH 2 ) m O) n (CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —(CH 2 ) m C(═O)NR 12 (CH 2 ) m C(═O)NR 12 (CH 2 ) m —, —(CH 2 ) m NR 12 C(═O)(CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —C(═O)NR 12 (CH 2 ) m NR 12 C(═O)—, —(CH 2 ) m S(CH 2 ) m —, —NR 12 C(═O)(CH 2 ) m —, —NR 12 C(═O)(CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m C(═O)NR 12 —, —(CH 2 ) m C(═O)NR 12 —, —(CH 2 ) m NR 12 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m —, —((CH 2 ) m O) n (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m (O(CH 2 ) m ) n —, —NR 12 (CH 2 ) m —, —NR 12 C(R 12 ) 2 (CH 2 ) m —, —(CH 2 ) m C(R 12 ) 2 NR 12 —, —(CH 2 ) m C(═O)NR 12 (CH 2 ) m NR 12 —, —NR 12 (CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —NR 12 C(R 12 ) 2 (CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —(CH 2 ) m C(═O)NR 12 (CH 2 ) m C(R 12 ) 2 NR 12 —, —NR 12 (CH 2 ) m X 3 (CH 2 ) m —, —NR 12 C(R 12 ) 2 (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m C(R 12 ) 2 NR 12 —, —NR 12 C(R 12 ) 2 (CH 2 ) m OC(═O)NR 12 (CH 2 ) m —, —(CH 2 ) m NR 12 C(═O)O(CH 2 ) m C(R 12 ) 2 NR 12 —, —NR 12 C(R 12 ) 2 (CH 2 ) m OC(═O)NR 12 (CH 2 ) m X 3 (CH 2 ) m —, —NR 12 (CH 2 ) m O) n (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m (O(CH 2 ) m ) n NR 12 —, —NR 12 (CH 2 ) m O) n (CH 2 ) m —, —(CH 2 ) m (O(CH 2 ) m ) n NR 12 —, —(CH 2 ) m X 3 (CH 2 ) m NR 12 C(═O)O(CH 2 ) m C(R 12 ) 2 NR 12 —, —NR 12 C(R 12 ) 2 (CH 2 ) m OC(═O)NR 12 ((CH 2 ) m O) n (CH 2 ) m —, —(CH 2 ) m (O(CH 2 ) m ) n NR 12 C(═O)O(CH 2 ) m C(R 12 ) 2 NR 12 —, —NR 12 C(R 12 ) 2 (CH 2 ) m OC(═O)NR 12 ((CH 2 ) m O) n (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m (O(CH 2 ) m ) n NR 12 C(═O)O(CH 2 ) m C(R 12 ) 2 NR 12 —, —(CH 2 ) m X 3 (CH 2 ) m NR 12 —, —NR 12 ((CH 2 ) m O) n (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m (O(CH 2 ) m ) n NR 12 —, —(CH 2 ) m NR 12 —, —NR 12 ((CH 2 ) m O) n (CH 2 ) m —, —NR 12 ((CH 2 ) m O) n (CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —(CH 2 ) m C(═O)NR 12 (CH 2 ) m (O(CH 2 ) m ) n NR 12 —, —(CH 2 ) m (O(CH 2 ) m ) n NR 12 —, —(C(R 12 ) 2 ) m —, —(CH 2 CH 2 O) n —, —(OCH 2 CH 2 ) n —, —(CH 2 ) m O(CH 2 ) m —, —S(═O) 2 (CH 2 ) m —, —(CH 2 ) m S(═O) 2 —, —S(═O) 2 (CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —(CH 2 ) m C(═O)NR 12 (CH 2 ) m S(═O) 2 —, —S(═O) 2 (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m S(═O) 2 —, —(CH 2 ) m X 2 X 1 C(═O)—, —C(═O)X 1 X 2 (CH 2 ) m —, —(CH 2 ) m (O(CH 2 ) m ) n C(═O)X 2 X 1 C(═O)—, —C(═O)X 1 X 2 C(═O)((CH 2 ) m O) n (CH 2 ) m —, —(CH 2 ) m (O(CH 2 ) m ) n X 2 X 1 C(═O)—, —(CH 2 ) m X 3 (CH 2 ) m X 2 X 1 C(═O)—, —C(═O)X 1 X 2 (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m (O(CH 2 ) m ) n X 2 X 1 C(═O)—, —(CH 2 ) m X 3 (CH 2 ) m C(═O)NR 12 (CH 2 ) m NR 12 C(═O)—, —(CH 2 ) m X 3 (CH 2 ) m C(═O)NR 12 (CH 2 ) m C(═O)—, —C(═O)(CH 2 ) m NR 12 C(═O(CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m C(═O)NR 12 (CH 2 ) m (O(CH 2 ) m ) n C(═O)—, —C(═O)((CH 2 ) m O) n (CH 2 ) m NR 12 C(═O)(CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m NR 12 C(═O)X 1 X 2 C(═O)(CH 2 ) m —, —(CH 2 ) m C(═O)X 2 X 1 C(═O)NR 12 (CH 2 ) m —, —X 4 X 1 X 2 C(═O)(CH 2 ) m —, —(CH 2 ) m C(═O)X 2 X 1 X 4 —, —X 1 C(═O)(CH 2 ) m NHC(═O)(CH 2 ) m —, —(CH 2 ) m C(═O)NH(CH 2 ) m C(═O)X 1 —, —C(═O)CHR aa NR 12 —, —CHR aa C(═O)—, —C(═O)NR 12 —, —C(═O)O—, —S—, —SCH 2 (C═O)NR 12 —, —NR 12 C(═O)CH 2 S—, —S(═O) 2 CH 2 S—, —SCH 2 CH 2 S(═O) 2 —, —(CH 2 ) 2 S(═O) 2 CH 2 CH 2 S—, —SCH 2 CH 2 S(═O) 2 CH 2 CH 2 —, —NR 12 C(═S)—, —(CH 2 ) m X 3 (O(CH 2 ) m ) n C(═O)—, —C(═O)((CH 2 ) m O) n X 3 (CH 2 ) m —, —(CH 2 ) m NR 12 C(═O)((CH 2 ) m O) n (CH 2 ) m —, —(CH 2 ) m (O(CH 2 ) m ) n C(═O)NR 12 (CH 2 ) m —, —(CH 2 ) m NR 12 C(═O)NR 12 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m NR 12 C(═O)—, —C(═O)NR 12 (CH 2 ) m X 3 (CH 2 ) m —, —NR 12 S(═O) 2 (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m S(═O) 2 NR 12 —,

R 20 is H or Me, and R 30 is H, —CH 3 or phenyl;

R 21 is

each R 25 is independently selected from H or C 1-4 alkyl;

R aa is a side chain of an amino acid selected from glycine, alanine, tryptophan, tyrosine, phenylalanine, leucine, isoleucine, valine, asparagine, glutamic acid, glutamine, aspatic acid, histidine, arginine, lysine, cysteine, methionine, serine, threonine, phenylglycine and t-butylglycine;

R 32 is independently selected from H, C 1-4 alkyl, phenyl, pyrimidine and pyridine;

R 33 is independently selected from

R 34 is independently selected from H, C 1-4 alkyl, and C 1-6 haloalkyl;

X 1 is self immolative spacer selected from

X 2 is dipeptide selected from

X 3 is

and

X 4 is

and L 2 , L 3 , L 4 , L 5 , and L 6 are each independently selected from a bond and L 1 ;

R 9 is

—NR 12 C(═O)CH═CH 2 , —N 3 ,

SH, —SSR 15 , —S(═O) 2 (CH═CH 2 ), —(CH 2 ) 2 S(═O) 2 (CH═CH 2 ), —NR 12 S(═O) 2 (CH═CH 2 ), —NR 12 C(═O)CH 2 R 10 , —NR 12 C(═O)CH 2 Br, —NR 12 C(═O)CH 2 I, —NHC(═O)CH 2 Br, —NHC(═O)CH 2 I, —ONH 2 , —C(O)NHNH 2 ,

—CO 2 H, —NH 2 , —NCO, —NCS,

R 10 is

each R 11 is independently selected from C 1 -C 6 alkyl and C 1 -C 6 alkyl which is optionally substituted with 1 to 5 hydroxyl;

each R 12 is independently selected from H and C 1 -C 6 alkyl;

R 13 is tetrazolyl, imidazolyl substituted with phenyl, oxadiazolyl substituted with phenyl, pyrazolyl, pyrimidinyl,

—CH 2 S(═O) 2 NH 2 , —CH 2 S(═O) 2 NHLR 9 , -LR 9 or —X 4 LR 9 ;

each R 14 is independently selected from H and C 1 -C 6 alkyl;

R 15 is 2-pyridyl or 4-pyridyl;

R 16 is an N-linked 4-8 membered heterocycloalkyl containing 1-2 heteroatoms independently selected from N and O, which is unsubstitituted or substituted with -LR 9 ;

each R 19 is H or C 1 -C 6 alkyl;

X 3 is

X 4 is

each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10;

each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 and 18,

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound of Formula (I) is a compound having the structure of Formula (Ia) or Formula (Ib):

3. The compound of claim 1 , wherein L is -L 1 - and -L 1 - is selected from:

—(CH 2 ) m C(═O)—, —C(═O)(CH 2 ) m —, —(CH 2 ) m —, —(CH 2 ) m C(═O)X 2 X 1 C(═O)—, —C(═O)X 1 X 2 C(═O)(CH 2 ) m —, —(CH 2 ) m (O(CH 2 ) m ) n C(═O)—, —C(═O)((CH 2 ) m O) n (CH 2 ) m —, —(CH 2 ) m X 3 (O(CH 2 ) m ) n C(═O)—, —C(═O)((CH 2 ) m O) n X 3 (CH 2 ) m —,

—(CH 2 ) m (O(CH 2 ) m ) n S(═O) 2 (CH 2 ) m —, —(CH 2 ) m S(═O) 2 ((CH 2 ) m O) n (CH 2 ) m —, —(CH 2 ) m NH(CH 2 ) m C(═O)—, —C(═O)(CH 2 ) m NH(CH 2 ) m —, —(CH 2 ) m NR 12 (CH 2 ) m C(═O)—, —C(═O)(CH 2 ) m NR 12 (CH 2 ) m —, —(CH 2 ) m C(═O)NH(CH 2 ) m —, —(CH 2 ) m NHC(═O)(CH 2 ) m —, —(CH 2 ) m NHC(═O)((CH 2 ) m O) n (CH 2 ) m —, —(CH 2 ) m (O(CH 2 ) m ) n C(═O)NH(CH 2 ) m —, —(CH 2 ) m NHC(═O)NH(CH 2 ) m —, —(CH 2 ) m S(═O) 2 —, —S(═O) 2 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m S(═O) 2 —, —S(═O) 2 (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m NHC(═O)(CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m C(═O)NH(CH 2 ) m —, —(CH 2 ) m X 2 X 1 C(═O)—, —C(═O)X 1 X 2 (CH 2 ) m —, —(CH 2 ) m (O(CH 2 ) m ) n C(═O)X 2 X 1 C(═O)—, —C(═O)X 1 X 2 C(═O)((CH 2 ) m O) n (CH 2 ) m —, —(CH 2 ) m (O(CH 2 ) m ) n X 2 X 1 C(═O)—, —C(═O)X 1 X 2 ((CH 2 ) m O) n (CH 2 ) m —, —(CH 2 ) m (O(CH 2 ) m ) n S(═O) 2 (CH 2 ) m —, —(CH 2 ) m S(═O) 2 ((CH 2 ) m O) n (CH 2 ) m —, —((CH 2 ) m O) n (CH 2 ) m —, —(CH 2 ) m (O(CH 2 ) m ) n —, —(CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m C(═O)—, —C(═O)(CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m C(═O)X 2 X 1 C(═O)—, —C(═O)X 1 X 2 C(═O)(CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m X 2 X 1 C(═O)—, —C(═O)X 1 X 2 (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m (O(CH 2 ) m ) n X 2 X 1 C(═O)—, —C(═O)X 1 X 2 ((CH 2 ) m O) n (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m NHC(═O)—, —C(═O)NH(CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m (O(CH 2 ) m ) n C(═O)—, —C(═O)((CH 2 ) m O) n (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 ((CH 2 ) m O) n (CH 2 ) m —, —(CH 2 ) m (O(CH 2 ) m ) n X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m C(═O)NH(CH 2 ) m —, —(CH 2 ) m NHC(═O)(CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m C(═O)NH(CH 2 ) m NHC(═O)—, —C(═O)NH(CH 2 ) m NHC(═O)(CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m NHC(═O)—, —C(═O)NH(CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m C(═O)NH(CH 2 ) m C(═O)—, —C(═O)(CH 2 ) m NHC(═O)(CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m C(═O)NH(CH 2 ) m NHC(═O)—, —C(═O)NH(CH 2 ) m NHC(═O)(CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m C(═O)NH(CH 2 ) m C(═O)—, —C(═O)(CH 2 ) m NHC(═O (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m C(═O)NH(CH 2 ) m (O(CH 2 ) m ) n C(═O)—, —C(═O)((CH 2 ) m O) n (CH 2 ) m NHC(═O)(CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m C(═O)NH(CH 2 ) m (O(CH 2 ) m ) n C(═O)—, —C(═O)((CH 2 ) m O) n (CH 2 ) m NHC(═O)(CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m C(═O)NH(CH 2 ) m NHC(═O)(CH 2 ) m —, —(CH 2 ) m C(═O)NH(CH 2 ) m C(═O)NH(CH 2 ) m —, —(CH 2 ) m NHC(═O)(CH 2 ) m NHC(═O)(CH 2 ) m —, —NR 12 S(═O) 2 (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m S(═O) 2 NR 12 —, —(CH 2 ) m X 3 (CH 2 ) m C(═O)NH(CH 2 ) m — and —(CH 2 ) m NHC(═O)(CH 2 ) m X 3 (CH 2 ) m —.

4. The compound of claim 1 , wherein:

R 1 is a C-linked 6 membered heterocycloalkyl containing 1-2 N heteroatoms and a C 1 -C 2 alkylene bridge, wherein the C-linked 6 membered heterocycloalkyl is substituted with an R 7 and 0 to 3 substituents independently selected from R 5 and R 6 ,

R 2 is —C 1 -C 6 alkyl;

R 3 is

R 4 is —OH, C 1 -C 6 alkoxy, —N(R 14 ) 2 , —R 16 , —NR 12 (CH 2 ) m N(R 14 ) 2 , —NHS(O) 2 (CH 2 ) m N 3 , —NR 12 (CH 2 ) m R 16 , —NHS(O) 2 R 11 ,

R 5 is C 1 -C 6 alkyl, C 1 -C 6 alkyl which is optionally substituted with 1 to 5 hydroxyl, —C(═O)R 11 , —(CH 2 ) m OH, —C(═O)(CH 2 ) m OH, —C(═O)((CH 2 ) m O) n R 12 , or —((CH 2 ) m O) n R 12 ;

R 6 is halo, oxo, OH, C 1 -C 6 alkyl, —N(R 14 ) 2 , —R 16 and —NR 12 C(═O)R 11 ;

R 7 is L 1 R 9 ;

R 8 is H;

R 9 is

—NR 12 C(═O)CH═CH 2 , —N 3

SH, —SSR 15 , —S(═O) 2 (CH═CH 2 ), —(CH 2 ) 2 S(═O) 2 (CH═CH 2 ), —NR 12 S(═O) 2 (CH═CH 2 ), —NR 12 C(═O)CH 2 Br, —NR 12 C(═O)CH 2 I, —NHC(═O)CH 2 Br, —NHC(═O)CH 2 I, —ONH 2 , —C(O)NHNH 2 ,

—CO 2 H, —NH 2 , —NCO, —NCS,

R 10 is

each R 11 is independently selected from C 1 -C 6 alkyl or C 1 -C 6 alkyl which is optionally substituted with 1 to 5 hydroxyl;

each R 12 is independently selected from H and C 1 -C 6 alkyl;

R 13 is tetrazolyl,

each R 14 is independently selected from H and C 1 -C 6 alkyl;

R 15 is 2-pyridyl or 4-pyridyl;

R 16 is an unsubstituted N-linked 4-8 membered heterocycloalkyl containing 1-2 heteroatoms independently selected from N and O,

R 19 is H or C 1 -C 6 alkyl;

each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and

each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 and 18.

5. The compound of claim 4 , wherein R 1 is

6. The compound of claim 5 , wherein:

R 2 is methyl, ethyl, isopropyl or sec-butyl;

R 3 is

R 4 is —OH, C 1 -C 6 alkoxy, —N(R 14 ) 2 , —R 16 , —NR 12 (CH 2 ) m N(R 14 ) 2 , —NR 12 (CH 2 ) m R 16 , —NHS(O) 2 R 11 ,

R 8 is H;

R 9 is

—NR 12 C(═O)CH═CH 2 , —N 3

—CO 2 H, —NH 2 , —NCO, —NCS,

each R 11 is independently selected from C 1 -C 6 alkyl or C 1 -C 6 alkyl which is optionally substituted with 1 to 5 hydroxyl;

each R 12 is independently selected from H and C 1 -C 6 alkyl;

R 13 is tetrazolyl,

each R 14 is independently selected from H and C 1 -C 6 alkyl;

R 15 is 2-pyridyl or 4-pyridyl;

R 16 is an unsubstituted N-linked 4-8 membered heterocycloalkyl containing 1-2 heteroatoms independently selected from N and O,

R 19 is H or C 1 -C 6 alkyl;

each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and

each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 and 18.

7. The compound of claim 6 , wherein:

R 2 is methyl, ethyl, isopropyl or sec-butyl;

R 3 is

R 4 is —OH, C 1 -C 6 alkoxy, —N(R 14 ) 2 , —R 16 , —NR 12 (CH 2 ) m N(R 14 ) 2 , —NR 12 (CH 2 ) m R 16 , —NHS(O) 2 R 11 ,

R 8 is H;

R 9 is

—NR 12 C(═O)CH═CH 2 , —N 3 ,

—CO 2 H, —NH 2 , —NCO, —NCS,

each R 11 is independently selected from C 1 -C 6 alkyl or C 1 -C 6 alkyl which is optionally substituted with 1 to 5 hydroxyl;

each R 12 is independently selected from H and C 1 -C 6 alkyl;

R 13 is tetrazolyl,

each R 14 is independently selected from H and C 1 -C 6 alkyl;

R 15 is 2-pyridyl or 4-pyridyl;

R 16 is an unsubstituted N-linked 4-8 membered heterocycloalkyl containing 1-2 heteroatoms independently selected from N and O,

R 19 is H or C 1 -C 6 alkyl;

each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and

each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 and 18.

8. The compound of claim 3 , wherein:

R 2 is methyl, ethyl, isopropyl or sec-butyl;

R 3 is

R 4 is —OH, C 1 -C 6 alkoxy, —NHS(O) 2 R 11 , —NHS(O) 2 (CH 2 ) m N 3 , or

R 8 is H;

L 1 is selected from:

—(CH 2 ) m —, —C(═O)(CH 2 ) m —, —C(═O)X 1 X 2 C(═O)(CH 2 ) m —, —C(═O)((CH 2 ) m O) n (CH 2 ) m —, —(CH 2 ) m S(═O) 2 ((CH 2 ) m O) n (CH 2 ) m —, —C(═O)(CH 2 ) m NR 12 (CH 2 ) m —, —C(═O)NR 12 (CH 2 ) m —, —C(═O)(CH 2 ) m X 3 ((CH 2 ) m O) n —,

—(CH 2 ) m C(═O)—, —(CH 2 ) m C(═O)X 2 X 1 C(═O)—, —(CH 2 ) m (O(CH 2 ) m ) n C(═O)—, —(CH 2 ) m (O(CH 2 ) m ) n S(═O) 2 (CH 2 ) m —, —(CH 2 ) m NR 12 (CH 2 ) m C(═O)—, —(CH 2 ) m NR 12 C(═O)—,

—(CH 2 ) m X 3 (CH 2 ) m C(═O)—, —C(═O)(CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m (O(CH 2 ) m ) n C(═O)—, —C(═O)((CH 2 ) m O) n (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m C(═O)NR 12 (CH 2 ) m C(═O)—, —C(═O)(CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —C(═O)(CH 2 ) m NR 12 C(═O)O(CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m , ——NR 12 (CH 2 ) m O) n (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m (O(CH 2 ) m ) n NR 12 —;

X 1 is self immolative spacer selected from

X 2 is dipeptide selected from

X 3 is

R 9 is

—N 3 , SH, —S(═O) 2 (CH═CH 2 ), —NR 12 C(═O)CH 2 Br, —ONH 2 ,

R 10 is

each R 11 is independently selected from C 1 -C 6 alkyl or C 1 -C 6 alkyl which is optionally substituted with 1 to 5 hydroxyl;

each R 12 is independently selected from H and C 1 -C 6 alkyl;

R 13 is tetrazolyl, imidazolyl substituted with phenyl, oxadiazolyl substituted with phenyl, pyrazolyl, pyrimidinyl,

or —CH 2 S(═O) 2 NH 2 ;

R 19 is H or C 1 -C 6 alkyl;

each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and

each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 and 18.

9. The compound of claim 1 , wherein:

R 1 is

R 2 is methyl, ethyl, isopropyl or sec-butyl;

R 3 is

R 4 is —OH;

R 9 is

, and

L is L 1 , wherein L 1 is selected from —(CH 2 ) m C(═O)—, —C(═O)(CH 2 ) m —, —(CH 2 ) m (O(CH 2 ) m ) n C(═O)—, and —C(═O)((CH 2 ) m O) n (CH 2 ) m —;

each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and

each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 and 18.

10. The compound of claim 1 , wherein:

R 1 is a C-linked 6 membered heterocycloalkyl containing 1-2 N heteroatoms and a C 1 -C 2 alkylene bridge, wherein the C-linked 6 membered heterocycloalkyl is unsubstituted or is substituted with 1 to 3 substituents independently selected from R 5 and R 6 ;

R 2 is —C 1 -C 6 alkyl;

R 3 is

L is L 1 ;

R 4 is -L 1 R 9 , —NHS(═O) 2 L 1 R 9 ,

R 5 is C 1 -C 6 alkyl, —C(═O)R 11 , —(CH 2 ) m OH, —C(═O)(CH 2 ) m OH, —C(═O)((CH 2 ) m O) n R 12 , —((CH 2 ) m O) n R 12 or C 1 -C 6 alkyl which is optionally substituted with 1 to 5 hydroxyl;

R 6 is halo, oxo, OH, C 1 -C 6 alkyl, —N(R 14 ) 2 and —NR 12 C(═O)R 11 ;

R 8 is L 1 R 9 ;

R 9 is

—NR 12 C(═O)CH═CH 2 , —N 3 ,

SH, —S(═O) 2 (CH═CH 2 ), —(CH 2 ) 2 S(═O) 2 (CH═CH 2 ), —NR 12 S(═O) 2 (CH═CH 2 ), —NR 12 C(═O)CH 2 R 10 , —NR 12 C(═O)CH 2 Br, —NR 12 C(═O)CH 2 I, —NHC(═O)CH 2 Br, —NHC(═O)CH 2 I, —ONH 2 , —C(O)NHNH 2 ,

—CO 2 H, —NH 2 , —NCO, —NCS,

R 10 is

each R 11 is independently selected from C 1 -C 6 alkyl and C 1 -C 6 alkyl which is optionally substituted with 1 to 5 hydroxyl;

each R 12 is independently selected from H and C 1 -C 6 alkyl;

R 13 is

—CH 2 S(═O) 2 NHLR 9 , -LR 9 or —X 4 LR 9 ;

each R 14 is independently selected from H and C 1 -C 6 alkyl;

R 16 is an N-linked 4-8 membered heterocycloalkyl containing 1-2 heteroatoms independently selected from N and O, which is substituted with -LR 9 ;

X 3 is

X 4 is

each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and

each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 and 18.

11. The compound of claim 10 , wherein R 1

12. The compound of claim 11 , wherein:

R 2 is methyl, ethyl, isopropyl or sec-butyl;

R 3 is

R 4 is -L 1 R 9 , —NHS(═O) 2 L 1 R 9 ,

R 6 is halo, oxo, OH, C 1 -C 6 alkyl, —N(R 14 ) 2 and —NR 12 C(═O)R 11 ;

R 8 is L 1 R 9 ;

R 9 is

—NR 12 C(═O)CH═CH 2 , —N 3 ,

—CO 2 H, —NH 2 , —NCO, —NCS,

R 10 is

each R 11 is independently selected from C 1 -C 6 alkyl and C 1 -C 6 alkyl which is optionally substituted with 1 to 5 hydroxyl;

each R 12 is independently selected from H and C 1 -C 6 alkyl;

R 13 is

—LR 9 or -X 4 LR 9 ;

each R 14 is independently selected from H and C 1 -C 6 alkyl;

R 16 is an N-linked 4-8 membered heterocycloalkyl containing 1-2 heteroatoms independently selected from N and O, which is substituted with -LR 9 ;

X 3 is

X 4 is

each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and

each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 and 18.

13. The compound of claim 11 , wherein:

R 2 is methyl, ethyl, isopropyl or sec-butyl;

R 3 is

R 4 is —NHS(═O) 2 L 1 R 9 ,

wherein L is L 1 ;

L 1 is selected from:

—(CH 2 ) m X 3 (CH 2 ) m C(═O)—, —C(═O)(CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m (O(CH 2 ) m ) n C(═O)—, —C(═O)((CH 2 ) m O) n (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m C(═O)NR 12 (CH 2 ) m C(═O)—, —C(═O)(CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —C(═O)(CH 2 ) m NR 12 C(═O)O(CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m —, —NR 12 (CH 2 ) m O) n (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m (O(CH 2 ) m ) n NR 12 —;

X 1 is self immolative spacer selected from

X 2 is dipeptide selected from

X 3 is

R 6 is halo, oxo, OH, C 1 -C 6 alkyl, —N(R 14 ) 2 and —NR 12 C(═O)R 11 ;

R 8 is L 1 R 9 ;

R 9 is

each R 11 is independently selected from C 1 -C 6 alkyl and C 1 -C 6 alkyl which is optionally substituted with 1 to 5 hydroxyl;

each R 12 is independently selected from H and C 1 -C 6 alkyl;

R 13 is

or —CH 2 S(═O) 2 NHLR 9 ;

each R 14 is independently selected from H and C 1 -C 6 alkyl;

X 3 is

X 4 is

each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and

each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 and 18.

14. The compound of claim 1 , wherein:

R 1 is a C-linked 6 membered heterocycloalkyl containing 1-2 N heteroatoms and a C 1 -C 2 alkylene bridge, or R 1 is a C-linked 5-8 membered fused bicyclic heterocycloalkyl containing 1-2 N heteroatoms, wherein each is unsubstituted or each is substituted with 1 to 3 substituents independently selected from R 5 and R 6 ;

R 2 is —C 1 -C 6 alkyl;

R 3 is

R 4 is —OH, C 1 -C 6 alkoxy, —N(R 14 ) 2 , —R 16 , —NR 12 (CH 2 ) m N(R 14 ) 2 , —NR 12 (CH 2 ) m R 16,—NHS(O) 2 R 11 ,

R 5 is C 1 -C 6 alkyl, —C(═O)R 11 , —(CH 2 ) m OH, —C(═O)(CH 2 ) m OH, —C(═O)((CH 2 ) m O) n R 12 , —((CH 2 ) m O) n R 12 or C 1 -C 6 alkyl which is optionally substituted with —CN, —C(═O)NH 2 or 1 to 5 hydroxyl,

R 6 is halo, oxo, OH, C 1 -C 6 alkyl, —N(R 14 ) 2 , —R 16 and —NR 12 C(═O)R 11 ;

R 8 is H;

each R 11 is independently selected from C 1 -C 6 alkyl and C 1 -C 6 alkyl which is optionally substituted with 1 to 5 hydroxyl;

each R 12 is independently selected from H and C 1 -C 6 alkyl;

R 13 is tetrazolyl, imidazolyl substituted with phenyl, oxadiazolyl substituted with phenyl, pyrazolyl, pyrimidinyl,

or —CH 2 S(═O) 2 NH 2 ;

each R 4 is independently selected from H and C 1 -C 6 alkyl;

R 15 is 2-pyridyl or 4-pyridyl;

R 16 is an unsubstitituted N-linked 4 - 8 membered heterocycloalkyl containing 1-2 heteroatoms independently selected from N and O;

R 19 is H or C 1 -C 6 alkyl;

each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and

each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 and 18.

15. The compound of claim 14 , wherein R 1 is

16. The compound of claim 14 , wherein R 2 is methyl, ethyl, isopropyl or sec-butyl.

17. The compound of claim 14 , wherein:

R 1 is a C-linked 6 membered heterocycloalkyl containing 1-2 N heteroatoms and a C 1 -C 2 alkylene bridge, which is unsubstituted or is substituted with 1 to 3 substituents independently selected from R 5 and R 6 ;

R 2 is methyl, ethyl, isopropyl or sec-butyl;

R 3 is

R 4 is —OH, C 1 -C 6 alkoxy, or —NHS(O) 2 R 11 ;

R 6 is halo, oxo, OH, C 1 -C 6 alkyl, —N(R 14 ) 2 , —R 16 and —NR 12 C(═O)R 11 ;

R 8 is H;

each R 11 is independently selected from C 1 -C 6 alkyl and C 1 -C 6 alkyl which is optionally substituted with 1 to 5 hydroxyl;

each R 12 is independently selected from H and C 1 -C 6 alkyl;

R 13 is tetrazolyl, imidazolyl substituted with phenyl, oxadiazolyl substituted with phenyl, pyrazolyl, pyrimidinyl,

or —CH 2 S(═O) 2 NH 2 ;

each R 14 is independently selected from H and C 1 -C 6 alkyl;

R 16 is an unsubstitituted N-linked 4-8 membered heterocycloalkyl containing 1-2 heteroatoms independently selected from N and O;

R 19 is H or C 1 -C 6 alkyl;

each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and

each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 and 18.

18. The compound of claim 17 , wherein R 1 is

19. The compound of claim 1 selected from,

20. An immunoconjugate of Formula (II):

wherein:

Ab represents an antigen binding moiety;

L is selected from -L 1 L 2 L 3 L 4 L 5 L 6 -, —L 6 L 5 L 4 L 3 L 2 L 1 -, -L 1 L 2 L 3 L 4 L 5 -, -L 5 L 4 L 3 L 2 L 1 ,-L 1 L 2 L 3 L 4 -, -L 4 L 3 L 2 L 1 -, -L 1 L 2 L 3 -, -L 3 L 2 L 1 , -L 1 L 2 -, -L 2 L 1 - and -L 1 ,

wherein

L 1 is selected from —(CH 2 ) m —, —C(═O)(CH 2 ) m —, —C(═O)X 1 X 2 C(═O)(CH 2 ) m —, —C(═O)X 1 X 2 C(═O)(CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —C(═O)X 1 X 2 C(═O)(CH 2 ) m X 3 (CH 2 ) m —, —C(═O)X 1 X 2 C(═O)((CH 2 ) m O) n (CH 2 ) m —, —C(═O)X 1 X 2 C(═O)((CH 2 ) m O) n (CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —C(═O)X 1 X 2 C(═O)((CH 2 ) m O) n (CH 2 ) m NR 12 C(═O)(CH 2 ) m X 3 (CH 2 ) m —, —C(═O)X 1 X 2 C(═O)((CH 2 ) m O) n (CH 2 ) m X 3 (CH 2 ) m —, —C(═O)X 1 X 2 C(═O)(CH 2 ) m NR 12 C(═O)((CH 2 ) m O) n (CH 2 ) m —, —C(═O)X 1 X 2 C(═O)(CH 2 ) m NR 12 C(═O)((CH 2 ) m O) n (CH 2 ) m X 3 (CH 2 ) m —, —C(═O)X 1 X 2 (CH 2 ) m X 3 (CH 2 ) m —, —C(═O)X 1 X 2 ((CH 2 ) m O) n (CH 2 ) m —, —C(═O)X 1 X 2 ((CH 2 ) m O) n (CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —C(═O)X 1 X 2 ((CH 2 ) m O) n (CH 2 ) m NR 12 C(═O)(CH 2 ) m X 3 (CH 2 ) m —, —C(═O)X 1 X 2 ((CH 2 ) m O) n (CH 2 ) m X 3 (CH 2 ) m —, —C(═O)X 1 X 2 (CH 2 ) m NR 12 ((CH 2 ) m O) n (CH 2 ) m —, —C(═O)X 1 X 2 C(═O)(CH 2 ) m NR 12 ((CH 2 ) m O) n (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —C(═O)((CH 2 ) m O) n (CH 2 ) m —, —(CH 2 ) m S(═O) 2 ((CH 2 ) m O) n (CH 2 ) m —, —C(═O)(CH 2 ) m NR 12 (CH 2 ) m —, —C(═O)NR 12 (CH 2 ) m —, —C(═O)NR 12 (CH 2 ) m X 3 (CH 2 ) m —, —C(═O)NH(CH 2 ) m NR 12 C(═O)X 1 X 2 C(═O)(CH 2 ) m —, —C(═O)X 1 C(═O)NR 12 (CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —C(═O)X 1 C(═O)NR 12 (CH 2 ) m X 3 (CH 2 ) m —, —C(═O)NR 12 (CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —C(═O)NR 12 (CH 2 ) m NR 12 C(═O)(CH 2 ) m X 3 (CH 2 ) m —,

—((CH 2 ) m O) n (CH 2 ) m —, —(CH 2 ) m (O(CH 2 ) m ) n —, —(CH 2 ) m (O(CH 2 ) m ) n X 3 (CH 2 ) m —, —(CH 2 ) m X 3 ((CH 2 ) m O) n (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) n C(═O)—, —C(═O)(CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m (O(CH 2 ) m ) n C(═O)—, —C(═O)((CH 2 ) m O) n (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m C(═O)NR 12 (CH 2 ) m C(═O)—, —C(═O)(CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —C(═O)(CH 2 ) m NR 12 C(═O)O(CH 2 ) m —, —(CH 2 ) m OC(═O)NR 12 (CH 2 ) m C(═O)—, —S(═O) 2 (CH 2 ) m NR 12 C(═O)O(CH 2 ) m —, —(CH 2 ) m OC(═O)NR 12 (CH 2 ) m S(═O) 2 —, —(CH 2 ) m C(═O)NR 12 (CH 2 ) m (O(CH 2 ) m ) n C(═O)—, —C(═O)((CH 2 ) m O) n (CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —(CH 2 ) m C(═O)NR 12 (CH 2 ) m C(═O)NR 12 (CH 2 ) m —, —(CH 2 ) m NR 12 C(═O)(CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —C(═O)NR 12 (CH 2 ) m NR 12 C(═O)—, —(CH 2 ) m S(CH 2 ) m —, —NR 12 C(═O)(CH 2 ) m —, —NR 12 C(═O)(CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m C(═O)NR 12 —, —(CH 2 ) m C(═O)NR 12 —, —(CH 2 ) m NR 12 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m —, —((CH 2 ) m O) n (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m (O(CH 2 ) m ) n —, —NR 12 (CH 2 ) m —, —NR 12 C(R 12 ) 2 (CH 2 ) m —, —(CH 2 ) m C(R 12 ) 2 NR 12 —, —(CH 2 ) m C(═O)NR 12 (CH 2 ) m NR 12 —, —NR 12 (CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —NR 12 C(R 12 ) 2 (CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —(CH 2 ) m C(═O)NR 12 (CH 2 ) m C(R 12 ) 2 NR 12 —, —NR 12 (CH 2 ) m X 3 (CH 2 ) m —, —NR 12 C(R 12 ) 2 (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m C(R 12 ) 2 NR 12 —, —NR 12 C(R 12 ) 2 (CH 2 ) m OC(═O)NR 12 (CH 2 ) m —, —(CH 2 ) m NR 12 C(═O)O(CH 2 ) m C(R 12 ) 2 NR 12 —, —NR 12 C(R 12 ) 2 (CH 2 ) m OC(═O)NR 12 (CH 2 ) m X 3 (CH 2 ) m —, —NR 12 (CH 2 ) m O) n (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m (O(CH 2 ) m ) n NR 12 —, —NR 12 (CH 2 ) m O) n (CH 2 ) m —, —(CH 2 ) m (O(CH 2 ) m ) n NR 12 —, —NR 12 (CH 2 ) m O) n (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m NR 12 C(═O) O (CH 2 ) m C(R 12 ) 2 NR 12 —, —NR 12 C(R 12 ) 2 (CH 2 ) m OC(═O)NR 12 ((CH 2 ) m O) n (CH 2 ) m —, —(CH 2 ) m (O(CH 2 ) m ) n NR 12 C(═O)O(CH 2 ) m C(R 12 ) 2 NR 12 —, —NR 12 C(R 12 ) 2 (CH 2 ) m OC(═O)NR 12 ((CH 2 ) m O) n (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m (O(CH 2 ) m ) n NR 12 C(═O)O(CH 2 ) m C(R 12 ) 2 NR 12 —, —(CH 2 ) m X 3 (CH 2 ) m NR 12 —, —NR 12 ((CH 2 ) m O) n (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m (O(CH 2 ) m ) n NR 12 —, —(CH 2 ) m NR 12 —, —NR 12 ((CH 2 ) m O) n (CH 2 ) m —, —NR 12 ((CH 2 ) m O) n (CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —(CH 2 ) m C(═O)NR 12 (CH 2 ) m (O(CH 2 ) m ) n NR 12 —, —(CH 2 ) m (O(CH 2 ) m ) n NR 12 —, —(C(R 12 ) 2 ) m —, —(CH 2 CH 2 O) n —, —(OCH 2 CH 2 ) n —, —(CH 2 ) m O(CH 2 ) m —, —S(═O) 2 (CH 2 ) m —, —(CH 2 ) m S(═O) 2 —, —S(═O) 2 (CH 2 ) m NR 12 C(═O)(CH 2 ) m —, —(CH 2 ) m C(═O)NR 12 (CH 2 ) m S(═O) 2 —, —S(═O) 2 (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m S(═O) 2 —, —(CH 2 ) m X 2 X 1 C(═O)—, —C(═O)X 1 X 2 (CH 2 ) m —, —(CH 2 ) m (O(CH 2 ) m ) n C(═O)X 2 X 1 C(═O)—, —C(═O)X 1 X 2 C(═O)((CH 2 ) m O) n (CH 2 ) m —, —(CH 2 ) m (O(CH 2 ) m ) n X 2 X 1 C(═O)—, —(CH 2 ) m X 3 (CH 2 ) m X 2 X 1 C(═O)—, —C(═O)X 1 X 2 (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m (O(CH 2 ) m ) n X 2 X 1 C(═O)—, —(CH 2 ) m X 3 (CH 2 ) m C(═O)NR 12 (CH 2 ) m NR 12 C(═O)—, —(CH 2 ) m X 3 (CH 2 ) m C(═O)NR 12 (CH 2 ) m C(═O)—, —C(═O)(CH 2 ) m NR 12 C(═O(CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m C(═O)NR 12 (CH 2 ) m (O(CH 2 ) m ) n C(═O)—, —C(═O)((CH 2 ) m O) n (CH 2 ) m NR 12 C(═O)(CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m NR 12 C(═O)X 1 X 2 C(═O)(CH 2 ) m —, —(CH 2 ) m C(═O)X 2 X 1 C(═O)NR 12 (CH 2 ) m —, —X 4 X 1 X 2 C(═O)(CH 2 ) m —, —(CH 2 ) m C(═O)X 2 X 1 X 4 —, —X 1 C(═O)(CH 2 ) m NHC(═O)(CH 2 ) m —, —(CH 2 ) m C(═O)NH(CH 2 ) m C(═O)X 1 —, —C(═O)CHR aa NR 12 —, —CHR aa C(═O)—, —C(═O)NR 12 —, —C(═O)O—, —S—, —SCH 2 (C═O)NR 12 —, —NR 12 C(═O)CH 2 S—, —S(═O) 2 CH 2 CH 2 S—, —SCH 2 CH 2 S(═O) 2 —, —(CH 2 ) 2 S(═O) 2 CH 2 CH 2 S—, —SCH 2 CH 2 S(═O) 2 CH 2 CH 2 —, —NR 12 C(═S)—, —(CH 2 ) m X 3 (O(CH 2 ) m ) n C(═O)—, —C(═O)((CH 2 ) m O) n X 3 (CH 2 ) m —, —(CH 2 ) m NR 12 C(═O)((CH 2 ) m O) n (CH 2 ) m —, —(CH 2 ) m (O(CH 2 ) m ) n C(═O)NR 12 (CH 2 ) m —, —(CH 2 ) m NR 12 C(═O)NR 12 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m NR 12 C(═O)—, —C(═O)NR 12 (CH 2 ) m X 3 (CH 2 ) m —, —NR 12 S(═O) 2 (CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m S(═O) 2 NR 12 —,

R 20 is H or Me, and R 30 is H, —CH 3 or phenyl;

R 21 is

each R 25 is independently selected from H or C 1-4 alkyl;

R 32 is independently selected from H, C 1-4 alkyl, phenyl, pyrimidine and pyridine;

R 33 is independently selected from

R 34 is independently selected from H, C 1-4 alkyl, and C 1-6 haloalkyl;

X 1 is self immolative spacer selected from

X 2 is dipeptide selected from

X 3 is

and

X 4 is

and L 2 , L 3 , L 4 , L 5 , and L 6 are each independently selected from a bond and L 1 ;

y is an integer from 1 to 16;

R 101 is a 6 membered heterocycloalkyl divalent radical containing 1-2 N heteroatoms and a C 1 -C 2 alkylene bridge, wherein the 6 membered heterocycloalkyl divalent radical is C-linked to the

group and is N-linked to L 1 or is C-linked to L 1 , and the 6 membered heterocycloalkyl divalent radical is unsubstituted or substituted with 1 to 3 substituents independently selected from R 5 and R 6 ;

or R 101 is a 5-8 membered fused bicyclic heterocycloalkyl divalent radical containing 1-2 N heteroatoms, wherein the 5-8 membered fused bicyclic heterocycloalkyl divalent radical is C-linked to the

group and is N-linked to L 1 or is C-linked to L 1 , and the 5-8 membered fused bicyclic heterocycloalkyl divalent radical is unsubstituted or substituted with 1 to 3 substituents independently selected from R 5 and R 6 ;

R 2 is —C 1 -C 6 alkyl;

R 3 is

R 4 is —OH, C 1 -C 6 alkoxy, —N(R 14 ) 2 , —R 16 , —NR 12 (CH 2 ) m N(R 14 ) 2 , or —NR 12 (CH 2 ) m R 16 , —NHS(O) 2 R 11 or

R 6 is halo, oxo, OH, C 1 -C 6 alkyl, —N(R 14 ) 2 , —R 16 and —NR 12 C(═O)R 11 ;

R 11 is C 1 -C 6 alkyl or C 1 -C 6 alkyl which is optionally substituted with 1 to 5 hydroxyl;

each R 2 is independently selected from H and C 1 -C 6 alkyl;

R 13 is tetrazolyl, imidazolyl substituted with phenyl, oxadiazolyl substituted with phenyl, pyrazolyl, pyrimidinyl,

—CH 2 S(═O) 2 NH 2 ;

each R 4 is independently selected from H and C 1 -C 6 alkyl;

R 16 is an N-linked 4-8 membered heterocycloalkyl containing 1-2 heteroatoms independently selected from N and O;

R 19 is H or C 1 -C 6 alkyl;

each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and

each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 and 18.

21. The immunoconjugate of claim 20 , wherein the immunoconjugate of Formula (II) is an immunoconjugate having the structure of Formula (IIb) or Formula (IIc):

22. The immunoconjugate of claim 21 , wherein R 101 is

23. The immunoconjugate of claim 22 , wherein R 3 is

and R 19 is H.

24. The immunoconjugate of claim 23 , wherein:

R 4 is —OH, C 1 -C 6 alkoxy, —N(R 14 ) 2 , —R 16 , —NR 12 (CH 2 ) m N(R 14 ) 2 , or —NR 12 (CH 2 ) m R 16 .

25. The immunoconjugate of claim 24 , wherein R 2 is methyl, ethyl, isopropyl or sec-butyl.

26. The immunoconjugate of claim 25 , wherein:

L 1 is —(CH 2 ) m NHC(═O)(CH 2 ) m X 3 (CH 2 ) m *—, —(CH 2 ) m C(═O)*—, —(CH 2 ) m —, —(CH 2 ) m C(═O)X 2 X 1 C(═O)*—, —(CH 2 ) m X 2 X 1 C(═O)*—, —(CH 2 ) m (O(CH 2 ) m ) n C(═O)*—, —(CH 2 ) m (O(CH 2 ) m ) n C(═O)X 2 X 1 C(═O)*—, —(CH 2 ) m (O(CH 2 ) m ) n X 2 X 1 C(═O)*—, —(CH 2 ) m (O(CH 2 ) m ) n S(═O) 2 (CH 2 ) m *—, —(CH 2 ) m NH(CH 2 ) m C(═O)*—, —((CH 2 ) m O) n (CH 2 ) m *—, —(CH 2 ) m X 3 (CH 2 ) m C(═O)*—, —(CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m C(═O)X 2 X 1 C(═O)*—, —(CH 2 ) m X 3 (CH 2 ) m X 2 X 1 C(═O)*—, —(CH 2 ) m X 3 (CH 2 ) m (O(CH 2 ) m ) n X 2 X 1 C(═O)*—, —(CH 2 ) m NHC(═O)*—, —(CH 2 ) m X 3 (CH 2 ) m (O(CH 2 ) m ) n C(═O)*—, —(CH 2 ) m X 3 ((CH 2 ) m O) n (CH 2 ) m *—, —(CH 2 ) m C(═O)NH(CH 2 ) m *—, —(CH 2 ) m X 3 (CH 2 ) m C(═O)NH(CH 2 ) m *—, —(CH 2 ) m C(═O)NH(CH 2 ) m NHC(═O)*—, —(CH 2 ) m X 3 (CH 2 ) m NHC(═O)*—, —(CH 2 ) m C(═O)NH(CH 2 ) m C(═O)*—, —(CH 2 ) m X 3 (CH 2 ) m C(═O)NH(CH 2 ) m NHC(═O)*—, —(CH 2 ) m X 3 (CH 2 ) m C(═O)NH(CH 2 ) m C(═O)*—, —(CH 2 ) m C(═O)NH(CH 2 ) m (O(CH 2 ) m ) n C(═O)*—, —(CH 2 ) m X 3 (CH 2 ) m C(═O)NH(CH 2 ) m (O(CH 2 ) m ) n C(═O)*—, —(CH 2 ) m C(═O)NH(CH 2 ) m NHC(═O)(CH 2 ) m *—, —(CH 2 ) m C(═O)NH(CH 2 ) m C(═O)NH(CH 2 ) m *—, —(CH 2 ) m X 3 (CH 2 ) m C(═O)NH(CH 2 ) m *—, —(CH 2 ) m S(═O) 2 *—, —(CH 2 ) m X 3 (CH 2 ) m S(═O) 2 *—, —(CH 2 ) m OC(═O)NH(CH 2 ) m C(═O)*—, and —(CH 2 ) m OC(═O)NH(CH 2 ) m S(═O) 2 *—, and wherein the * indicates the point of attachment to R 101 ;

L 2 is a bond,

—S—, —SCH 2 (C═O)NH—, —NHC(═O)CH 2 S—, —SCH 2 CH 2 C(═O)NH—, —NHC(═O)CH 2 CH 2 S—, —SCH 2 CH 2 S(═O) 2 —, —S(═O) 2 CH 2 CH 2 S—, —SCH 2 CH 2 S(═O) 2 NH— or —NHS(═O) 2 CH 2 CH 2 S—, wherein the * indicates the point of attachment to L 1 , and

L 3 , L 4 , L 5 and L 6 are a bond.

27. The immunoconjugate of claim 25 , wherein:

L 1 is selected from —(CH 2 ) m C(═O)*—, —(CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m C(═O)*—, —(CH 2 ) m C(═O)X 2 X 1 C(═O)*—, —(CH 2 ) m X 3 (CH 2 ) m —, —(CH 2 ) m X 3 (CH 2 ) m C(═O)X 2 X 1 C(═O)*—, —(CH 2 ) m (O(CH 2 ) m ) n C(═O)*—, —(CH 2 ) m X 3 (CH 2 ) m (O(CH 2 ) m ) n C(═O)*—, —(CH 2 ) m (O(CH 2 ) m ) n S(═O) 2 (CH 2 ) m *— and —(CH 2 ) m NR 12 (CH 2 ) m C(═O)*—, wherein the * indicates the point of attachment to R 101 ;

and

L 2 is

wherein the * indicates the point of attachment to L 1 ,

and L 3 , L 4 , L 5 and L 6 are a bond.

28. A pharmaceutical composition comprising an immunoconjugate of claim 20 , and one or more pharmaceutically acceptable carriers.

29. A pharmaceutical composition comprising an immunoconjugate of claim 27 , and one or more pharmaceutically acceptable carriers.

Assignments (4)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2017

From: GEIERSTANGER, BERNHARD HUBERT; GRUNEWALD, JAN; OU, WEIJIA; UNO, TETSUO; WAN, YONGQIN; WANG, XING; JIN, YUNHO

To: NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION

Reel/Frame 041765/0938 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2017

From: NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION

To: IRM LLC

Reel/Frame 041767/0581 →

MERGER Recorded Mar 28, 2017

From: IRM LLC

To: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.

Reel/Frame 041768/0739 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2017

From: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.

To: NOVARTIS AG

Reel/Frame 041769/0248 →

Continuity (2)

Provisional Application 61917293 · Dec 17, 2013

Related Publication 20160311853A1 · Oct 27, 2016